Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ingenol mebutate
Drug ID BADD_D01158
Description Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations.
Indications and Usage For the topical treatment of actinic keratosis.
Marketing Status approved
ATC Code D06BX02
DrugBank ID DB05013
KEGG ID D09393
MeSH ID C486592
PubChem ID 6918670
TTD Drug ID D0E9KA
NDC Product Code 61200-037; 47848-047
UNII 7686S50JAH
Synonyms 3-ingenyl angelate | ingenol 3-angelate | 3-ingenol angelate | PEP005 | PEP-005 | PEP 005 | picato | ingenol mebutate
Chemical Information
Molecular Formula C25H34O6
CAS Registry Number 75567-37-2
SMILES CC=C(C)C(=O)OC1C(=CC23C1(C(C(=CC(C2=O)C4C(C4(C)C)CC3C)CO)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Swelling face10.01.05.018; 08.01.03.100; 23.04.01.018--Not Available
Ulcer08.03.06.001--Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013--Not Available
Application site vesicles12.07.01.009; 08.02.01.009; 23.03.01.009--Not Available
Application site infection12.07.01.012; 11.01.08.012; 08.02.01.015--Not Available
Application site pustules08.02.01.041; 23.03.10.004; 12.07.01.041; 11.01.12.014--Not Available
Application site paraesthesia17.02.06.012; 12.07.01.026; 08.02.01.026--Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.005--Not Available
Application site discharge12.07.01.039; 08.02.01.039; 23.03.03.049--Not Available
Application site swelling12.07.01.027; 08.02.01.027--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Disease progression08.01.03.038--
Oral mucosal exfoliation07.05.05.011--Not Available
Application site exfoliation08.02.01.022; 23.03.07.007; 12.07.01.022--Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Application site erosion23.07.03.011; 12.07.01.021; 08.02.01.021--Not Available
Application site scab12.07.01.042; 08.02.01.042; 23.03.03.050--Not Available
The 2th Page    First    Pre   2    Total 2 Pages